The Aquadex SmartFlow System is FDA cleared to simply, safely, and precisely remove excess fluid (primarily salt and water) from patients suffering from fluid overload who have not responded to medical management, including diuretics.
Providers can specify and adjust the rate of fluid removed for each individual patient, resulting in a gradual reduction of excess fluid. Up to 500 mL per hour of excess fluid can be removed. Aquadex® therapy has been shown to have no significant clinical impact on blood pressure, heart rate, or the balance of electrolytes (e.g., sodium, potassium, etc.) in the body.1,2
Review the clinical data for Aquadex therapy here.
The Aquadex SmartFlow System consists of three components, the console, the peripheral catheter, and the blood circuit set. The console allows caregivers precise control of ultrafiltration therapy. The peripheral catheter draws blood from and returns blood to the patient. Finally, the blood circuit set filters the patient’s blood and collects excess water and salt.
Benefits and enhanced diagnostic features
If the Hct sensor clip is removed from the blood circuit for a few minutes, the resulting graph will show the “no data” points inconsistently depending on the selected time base on the horizontal axis. The user is given an alarm if the Hct clip is not on the cuvette, minimizing the likelihood of this occurring.
Auto Flow Rate Change
The Aquadex System does not allow the Ultrafiltrate Rate (UF) to be more than 21% of the Blood Flow (BF) rate. For example, setting BF to 40 ml/min and UF rate to 500 ml/hr puts the UF at 21% of BF. In this situation, if the user chooses to further decrease BF, the UF will automatically decrease to remain at no more than 21% of BF with the message “Current blood flow rate requires UF rate to be decreased”. The message only displays the first time the rate is automatically changed.
Software Version 2.0.1
Version 2.0.1 is an international release of the SmartFlow software, updated to support additional languages. The functionality of the software is identical to version 2.0.0 – please refer to the release notes for that version.
 RAPID Trial: Bart BA, et al. J Am Coll Cardiol. 2005 Dec 6; 46(11): 2043-2046.  SAFE Trial: Jaski BE, et al. J Card Fail. 2003 Jun; 9(3): 227-231.
Rx Only. Indication: Continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.